Syndicate content

ASEMV 2017—Engineered Exosomes with Super Repressor IkB, a Potent Inhibitor of NF-kB Pathway, for Treatment of Septic Shock

On Monday morning, October 9, Chulhee Choi, MD, PhD, of the Department of Bio and Bioengineering, KAIST, Korea; and CEO of Cellex Life Sciences, Inc., described the potential for a new system to treat acute inflammatory diseases, including septic shock. To emphasize the need for improvements in the treatment of septic shock, Dr. Choi noted that there are 20 million cases of this disease each year and that it is the leading cause of death in intensive care units. Previously, Dr. Choi’s group had developed an opto-generated engineered exosome system, named “exosomes for protein loading via optically reversible protein-protein interaction” (EXPLOR) that can deliver soluble proteins into the cytosol via controlled reversible protein-protein interactions (PPI). Treatment with protein-loaded EXPLORs was shown to significantly increase intracellular levels of cargo proteins and their function in recipient cells in both a time- and dose-dependent manner. In the current study, the group sought to test the feasibility of using EXPLOR technology for the delivery of super repressor IkB (SRI), a potent inhibitor of the NF-kB pathway, as a potential treatment for acute inflammatory diseases such as septic shock syndrome. The group was able to load SRI into engineered exosomes by transiently or stably expressing fusion proteins in exosome-producing cells. The scientists further demonstrated the intracellular delivery of SRI as functional proteins in the target cells in vitro and target organs in vivo. Finally, the researchers observed a beneficial effect of SRI-loaded exosomes in septic shock animal models compared to what is seen with naïve exosomes. Dr. Choi concludes that these results clearly indicate the potential of EXPLORs for the treatment of acute inflammatory diseases The American Society for Exosomes and Microvesicles (ASEMV) 2017 Annual Meeting was held October 8-12 at the Asilomar Conference Grounds in Pacific Grove, California. The event was attended by 180 scientists from around the United States and world. This year’s meeting was organized by ASEMV President Dr. Stephen J. Gould of Johns Hopkins University, and sponsors of the meeting included Particle Metrix, CARIS Life Sciences, ReNeuron, Malvern, QIAGEN, Hitachi Chemical, iZON, System Biosciences, Beckman Coulter, Norgen Biotek Corporation, Hansa Bio Med Life Sciences, Lonza, and nanoView Diagnostics.

[ASEMV 2017] [Program ASEMV 2017] [ASEMV About Us]